You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLornoxicam
Accession NumberDB06725
TypeSmall Molecule
GroupsApproved
DescriptionLornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. Lornoxicam is approved for use in Japan.
Structure
Thumb
Synonyms
Chlortenoxicam
Lornoxicamum
External Identifiers
  • CCRIS 8589
  • Ro 13-9297
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LorcamTaisho Pharmaceutical Co.
XafonNycomed
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIER09126G7A
CAS number70374-39-9
WeightAverage: 371.81
Monoisotopic: 370.9801259
Chemical FormulaC13H10ClN3O4S2
InChI KeyWLHQHAUOOXYABV-UHFFFAOYSA-N
InChI
InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)
IUPAC Name
6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1λ⁶-thieno[2,3-e][1,2]thiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O
Pharmacology
IndicationFor the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases.
Structured Indications Not Available
PharmacodynamicsLornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the oxicam class. As with other NSAIDS, lornoxicam is a potent inhibitor of the cyclooxgenase enzymes, which are responsible for catalyzing the formation of prostaglandins (act as messenger molecules in the process of inflammation) and thromboxane from arachidonic acid. Unlike some NSAIDS, lornoxicam's inhibition of cyclooxygenase does not lead to an increase in leukotriene formation, meaning that arachidonic acid is not moved to the 5-lipoxygenase cascade, resulting in the minimization of the risk of adverse events.
Mechanism of actionLike other NSAIDS, lornoxicam's anti-inflammatory and analgesic activity is related to its inhibitory action on prostaglandin and thromboxane synthesis through the inhibition of both COX-1 and COX-2. This leads to the reduction of inflammation, pain, fever, and swelling, which are mediated by prostaglandins. However, the exact mechanism of lornoxicam, like that of the other NSAIDs, has not been fully determined.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 1Proteinyes
inhibitor
HumanP23219 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Related Articles
AbsorptionLornoxicam is absorbed rapidly and almost completely from the GI tract (90-100%).
Volume of distributionNot Available
Protein bindingLornoxicam is 99% bound to plasma proteins (almost exlusively to serum albumin).
Metabolism

Lornoxicam is metabolized completely by cyp 2C9 with the principal metabolite being 5'-hydroxy-lornoxicam and only negligible amounts of intact lornoxicam are excreted unchanged in the urine. Approximately 2/3 of the drug is eliminated via the liver and 1/3 via the kidneys in the active form.

SubstrateEnzymesProduct
Lornoxicam
5'-HydroxylornoxicamDetails
Route of eliminationNot Available
Half life3-5 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Lornoxicam Action PathwayDrug actionSMP00700
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 5-androstenedione.Experimental, Illicit
AbciximabLornoxicam may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Lornoxicam can be decreased when combined with Abiraterone.Approved
AcebutololLornoxicam may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Aceclofenac.Approved
AcenocoumarolLornoxicam may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Lornoxicam.Approved, Vet Approved
AclarubicinLornoxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Lornoxicam.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.Approved
AliskirenLornoxicam may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololLornoxicam may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Lornoxicam.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Amcinonide.Approved
AmikacinLornoxicam may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideLornoxicam may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Lornoxicam can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinLornoxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodLornoxicam may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Anisodamine.Investigational
annamycinLornoxicam may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Lornoxicam.Approved
Antithrombin III humanLornoxicam may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Lornoxicam may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanLornoxicam may increase the anticoagulant activities of Apixaban.Approved
ApramycinLornoxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Lornoxicam.Approved, Investigational
AprepitantThe metabolism of Lornoxicam can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinLornoxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinLornoxicam may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanLornoxicam may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololLornoxicam may decrease the antihypertensive activities of Arotinolol.Approved
AtenololLornoxicam may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lornoxicam.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lornoxicam.Approved
BalsalazideLornoxicam may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminLornoxicam may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololLornoxicam may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Lornoxicam.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lornoxicam.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lornoxicam.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lornoxicam.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Betamethasone.Approved, Vet Approved
BetaxololLornoxicam may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Betulinic Acid.Investigational
BevantololLornoxicam may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
BisoprololLornoxicam may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinLornoxicam may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololLornoxicam may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lornoxicam.Approved
BucillamineThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Bucillamine.Investigational
BucindololLornoxicam may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Budesonide.Approved
BufuralolLornoxicam may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideLornoxicam may decrease the diuretic activities of Bumetanide.Approved
BupranololLornoxicam may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Lornoxicam.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Lornoxicam.Experimental
CapecitabineThe metabolism of Lornoxicam can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Lornoxicam.Approved
CarbamazepineThe metabolism of Lornoxicam can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lornoxicam.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Lornoxicam.Approved, Vet Approved, Withdrawn
CarteololLornoxicam may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolLornoxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lornoxicam.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Celecoxib.Approved, Investigational
CeliprololLornoxicam may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Lornoxicam can be increased when it is combined with Ceritinib.Approved
CertoparinLornoxicam may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lornoxicam.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lornoxicam.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lornoxicam.Approved
CholecalciferolThe metabolism of Lornoxicam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lornoxicam.Approved
CinoxacinLornoxicam may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinLornoxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidLornoxicam may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Lornoxicam.Vet Approved
ClotrimazoleThe metabolism of Lornoxicam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Curcumin.Investigational
CyclosporineLornoxicam may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Lornoxicam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with D-Limonene.Investigational
Dabigatran etexilateLornoxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Lornoxicam can be decreased when it is combined with Dabrafenib.Approved
DalteparinLornoxicam may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidLornoxicam may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinLornoxicam may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Lornoxicam can be decreased when combined with Delavirdine.Approved
DesirudinLornoxicam may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Lornoxicam.Approved
DextranLornoxicam may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Lornoxicam may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Lornoxicam may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Lornoxicam may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Lornoxicam.Approved, Vet Approved
DicoumarolLornoxicam may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lornoxicam.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lornoxicam.Approved
DihydrostreptomycinLornoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Lornoxicam.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Lornoxicam.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Lornoxicam.Approved
DoxorubicinLornoxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneLornoxicam may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Lornoxicam is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ebselen.Investigational
Edetic AcidLornoxicam may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanLornoxicam may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Lornoxicam can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Lornoxicam.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Lornoxicam.Approved
EnoxacinLornoxicam may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinLornoxicam may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Epirizole.Approved
EpirubicinLornoxicam may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneLornoxicam may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lornoxicam.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lornoxicam.Approved
EquileninThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Equilin.Approved
EsmololLornoxicam may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Estrone sulfate.Approved
Etacrynic acidLornoxicam may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Lornoxicam.Approved, Investigational
Ethyl biscoumacetateLornoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Lornoxicam can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Lornoxicam.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Lornoxicam.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Lornoxicam.Vet Approved
FleroxacinLornoxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Lornoxicam.Approved, Withdrawn
FloxuridineThe metabolism of Lornoxicam can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with fluasterone.Investigational
FluconazoleThe metabolism of Lornoxicam can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fludrocortisone.Approved
FluindioneLornoxicam may increase the anticoagulant activities of Fluindione.Investigational
FlumequineLornoxicam may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Lornoxicam can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Lornoxicam.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lornoxicam.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Lornoxicam can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Lornoxicam can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Lornoxicam.Approved, Nutraceutical, Vet Approved
FondaparinuxLornoxicam may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumLornoxicam may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Lornoxicam.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lornoxicam.Approved
FosphenytoinThe metabolism of Lornoxicam can be increased when combined with Fosphenytoin.Approved
FramycetinLornoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideLornoxicam may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateLornoxicam may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinLornoxicam may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinLornoxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Lornoxicam.Approved, Withdrawn
GemfibrozilThe metabolism of Lornoxicam can be decreased when combined with Gemfibrozil.Approved
GemifloxacinLornoxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinLornoxicam may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinLornoxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ALornoxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinLornoxicam may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Lornoxicam is combined with HE3286.Investigational
HeparinLornoxicam may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Higenamine.Investigational
HirulogLornoxicam may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Lornoxicam.Investigational
HydralazineLornoxicam may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lornoxicam.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lornoxicam.Approved
Hygromycin BLornoxicam may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lornoxicam.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Lornoxicam.Approved
IdarubicinLornoxicam may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxLornoxicam may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Lornoxicam.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lornoxicam.Approved
IndenololLornoxicam may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Lornoxicam can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lornoxicam.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Indoprofen.Withdrawn
INNO-206Lornoxicam may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Lornoxicam can be decreased when combined with Irbesartan.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Istaroxime.Investigational
KanamycinLornoxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Lornoxicam can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Lornoxicam.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Lornoxicam.Approved
LabetalolLornoxicam may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
LeflunomideThe metabolism of Lornoxicam can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinLornoxicam may increase the anticoagulant activities of Lepirudin.Approved
LevobunololLornoxicam may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinLornoxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Lornoxicam.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Lornoxicam.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Lornoxicam.Approved
LomefloxacinLornoxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved
LosartanThe metabolism of Lornoxicam can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Lornoxicam can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Lornoxicam.Approved, Investigational
LumacaftorThe serum concentration of Lornoxicam can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Lornoxicam.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lornoxicam.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lornoxicam.Approved
ME-609The risk or severity of adverse effects can be increased when Lornoxicam is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lornoxicam.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lornoxicam.Approved, Vet Approved
MesalazineLornoxicam may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Lornoxicam.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lornoxicam.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lornoxicam.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Methylprednisolone.Approved, Vet Approved
MetipranololLornoxicam may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lornoxicam.Approved
MetoprololLornoxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideLornoxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Lornoxicam can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Lornoxicam.Approved
MizoribineThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Lornoxicam.Approved
MometasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Lornoxicam.Approved
MoxifloxacinLornoxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lornoxicam.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lornoxicam.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Nabumetone.Approved
NadololLornoxicam may decrease the antihypertensive activities of Nadolol.Approved
NadroparinLornoxicam may increase the anticoagulant activities of Nadroparin.Approved
NafamostatLornoxicam may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lornoxicam.Approved
Nalidixic AcidLornoxicam may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Lornoxicam.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Lornoxicam is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Lornoxicam.Investigational
NeamineLornoxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinLornoxicam may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinLornoxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Nepafenac.Approved
NetilmicinLornoxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Lornoxicam can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lornoxicam.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lornoxicam.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Nitroaspirin.Investigational
NorfloxacinLornoxicam may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinLornoxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lornoxicam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lornoxicam.Approved
OlsalazineLornoxicam may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Lornoxicam.Investigational
OmeprazoleThe metabolism of Lornoxicam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Orgotein.Vet Approved
OtamixabanLornoxicam may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lornoxicam.Approved
OxprenololLornoxicam may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lornoxicam.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Parecoxib.Approved
ParomomycinLornoxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinLornoxicam may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinLornoxicam may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololLornoxicam may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateLornoxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Lornoxicam.Approved
PhenindioneLornoxicam may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Lornoxicam can be increased when combined with Phenobarbital.Approved
PhenprocoumonLornoxicam may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lornoxicam.Approved, Vet Approved
PhenytoinThe metabolism of Lornoxicam can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lornoxicam.Approved, Investigational
PindololLornoxicam may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinLornoxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideLornoxicam may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lornoxicam.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lornoxicam.Approved, Investigational
PlicamycinLornoxicam may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Lornoxicam.Approved
PractololLornoxicam may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Lornoxicam.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Lornoxicam can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Lornoxicam can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Propacetamol.Approved
PropranololLornoxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Lornoxicam.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Lornoxicam.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Lornoxicam.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Lornoxicam.Vet Approved
Protein CLornoxicam may increase the anticoagulant activities of Protein C.Approved
Protein S humanLornoxicam may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeLornoxicam may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinLornoxicam may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Lornoxicam.Investigational
PuromycinLornoxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Lornoxicam can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Lornoxicam.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lornoxicam.Approved
QuinineThe metabolism of Lornoxicam can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Lornoxicam.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lornoxicam.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lornoxicam.Experimental, Investigational
ReviparinLornoxicam may increase the anticoagulant activities of Reviparin.Approved
RibostamycinLornoxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Lornoxicam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Lornoxicam can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Risedronate.Approved, Investigational
RivaroxabanLornoxicam may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinLornoxicam may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Lornoxicam.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lornoxicam.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Lornoxicam.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lornoxicam.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Lornoxicam.Investigational
SecobarbitalThe metabolism of Lornoxicam can be increased when combined with Secobarbital.Approved, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Seratrodast.Approved, Investigational
SildenafilThe metabolism of Lornoxicam can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinLornoxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Lornoxicam can be decreased when combined with Sorafenib.Approved, Investigational
SotalolLornoxicam may decrease the antihypertensive activities of Sotalol.Approved
SP1049CLornoxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinLornoxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinLornoxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Lornoxicam.Approved
SpironolactoneLornoxicam may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Lornoxicam.Investigational
StreptomycinLornoxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinLornoxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Lornoxicam can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Lornoxicam can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineLornoxicam may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Lornoxicam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Lornoxicam.Approved
SulodexideLornoxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Lornoxicam.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Lornoxicam.Approved, Withdrawn
TacrolimusLornoxicam may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Lornoxicam.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Lornoxicam.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lornoxicam.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lornoxicam.Approved, Investigational
TemafloxacinLornoxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Lornoxicam.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Lornoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lornoxicam.Approved
TicagrelorThe metabolism of Lornoxicam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Lornoxicam can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tiludronate.Approved, Vet Approved
TimololLornoxicam may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tixocortol.Approved
TobramycinLornoxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Lornoxicam can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lornoxicam.Approved
TorasemideLornoxicam may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Lornoxicam.Approved
TranilastThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lornoxicam.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lornoxicam.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Triamcinolone.Approved, Vet Approved
TriamtereneLornoxicam may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lornoxicam.Approved, Vet Approved
TrimethoprimThe metabolism of Lornoxicam can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Lornoxicam.Approved
TrovafloxacinLornoxicam may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Lornoxicam.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Lornoxicam can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinLornoxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Lornoxicam can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Lornoxicam.Approved
VoriconazoleThe metabolism of Lornoxicam can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinLornoxicam may increase the anticoagulant activities of Warfarin.Approved
XimelagatranLornoxicam may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Lornoxicam may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Lornoxicam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Lornoxicam.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lornoxicam.Withdrawn
ZorubicinLornoxicam may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Balfour JA, Fitton A, Barradell LB: Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57. [PubMed:8706598 ]
  2. Vane JR: Introduction: mechanism of action of NSAIDs. Br J Rheumatol. 1996 Apr;35 Suppl 1:1-3. [PubMed:8630629 ]
  3. Radhofer-Welte S, Rabasseda X: Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000 Jan;36(1):55-76. [PubMed:12879104 ]
  4. Skjodt NM, Davies NM: Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet. 1998 Jun;34(6):421-8. [PubMed:9646006 ]
  5. Olkkola KT, Brunetto AV, Mattila MJ: Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994 Feb;26(2):107-20. [PubMed:8162655 ]
  6. Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D: Pharmacokinetics of lornoxicam in man. Postgrad Med J. 1990;66 Suppl 4:S22-7. [PubMed:2284217 ]
  7. Pruss TP, Stroissnig H, Radhofer-Welte S, Wendtlandt W, Mehdi N, Takacs F, Fellier H: Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J. 1990;66 Suppl 4:S18-21. [PubMed:2284216 ]
  8. Bonnabry P, Leemann T, Dayer P: Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol. 1996;49(4):305-8. [PubMed:8857077 ]
External Links
ATC CodesM01AC05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier-0.964
Caco-2 permeable+0.7528
P-glycoprotein substrateSubstrate0.5511
P-glycoprotein inhibitor INon-inhibitor0.8209
P-glycoprotein inhibitor IINon-inhibitor0.8506
Renal organic cation transporterNon-inhibitor0.9132
CYP450 2C9 substrateSubstrate0.6831
CYP450 2D6 substrateNon-substrate0.8868
CYP450 3A4 substrateNon-substrate0.6652
CYP450 1A2 substrateNon-inhibitor0.7958
CYP450 2C9 inhibitorInhibitor0.7138
CYP450 2D6 inhibitorNon-inhibitor0.8714
CYP450 2C19 inhibitorNon-inhibitor0.7777
CYP450 3A4 inhibitorNon-inhibitor0.8755
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7815
Ames testNon AMES toxic0.8009
CarcinogenicityNon-carcinogens0.6844
BiodegradationNot ready biodegradable0.9851
Rat acute toxicity3.8570 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9494
hERG inhibition (predictor II)Non-inhibitor0.8681
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.62BIOBYTE STARLIST (2009)
Predicted Properties
PropertyValueSource
Water Solubility0.0437 mg/mLALOGPS
logP3.08ALOGPS
logP0.64ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)1.82ChemAxon
pKa (Strongest Basic)4.22ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity87.9 m3·mol-1ChemAxon
Polarizability33.3 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acids and derivatives
Alternative Parents
Substituents
  • Alpha-amino acid or derivatives
  • Thienothiazine
  • N-arylamide
  • 2,3,5-trisubstituted thiophene
  • Ortho-thiazine
  • Aryl chloride
  • Aryl halide
  • Pyridine
  • Organosulfonic acid amide
  • Imidolactam
  • Heteroaromatic compound
  • Organic sulfonic acid or derivatives
  • Organosulfonic acid or derivatives
  • Thiophene
  • Vinylogous acid
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Organic oxygen compound
  • Organic nitrogen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Organic oxide
  • Hydrocarbon derivative
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. doi: 10.1016/j.contraception.2009.12.008. Epub 2010 Jan 27. [PubMed:20399943 ]
  2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. [PubMed:10450786 ]
  3. Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36. [PubMed:17516707 ]
  4. Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5. [PubMed:11846620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Renner RM, Jensen JT, Nichols MD, Edelman AB: Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials. Contraception. 2010 May;81(5):372-88. doi: 10.1016/j.contraception.2009.12.008. Epub 2010 Jan 27. [PubMed:20399943 ]
  2. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. [PubMed:10450786 ]
  3. Rose P, Steinhauser C: Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36. [PubMed:17516707 ]
  4. Bianchi M, Panerai AE: Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res. 2002 Feb;45(2):101-5. [PubMed:11846620 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Rodrigues AD: Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75. Epub 2005 Aug 23. [PubMed:16118328 ]
  2. Martinez C, Blanco G, Garcia-Martin E, Agundez JA: [Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs]. Farm Hosp. 2006 Jul-Aug;30(4):240-8. [PubMed:17022718 ]
  3. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H: Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol. 2005 Jan;59(1):14-7. [PubMed:15606435 ]
  4. Kohl C, Steinkellner M: Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8. [PubMed:10640513 ]
  5. Bonnabry P, Leemann T, Dayer P: Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol. 1996;49(4):305-8. [PubMed:8857077 ]
  6. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  7. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  8. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on August 18, 2010 12:12 / Updated on August 17, 2016 12:24